Temporal trends and outcomes of long coronary chronic total occlusion interventions: the Japanese CTO-PCI expert registry
Cardiovascular Intervention and Therapeutics · 2026
DOI: 10.1007/s12928-025-01226-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, 2026. Verfasst von Hiroyuki Tanaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Okayama, Japan. ht7307@kchnet.or.jp. Hauptthemen laut MEDLINE: Coronary Occlusion, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Asahi Intecc, Abbott Japan, Biosensors Japan.
Abstract (Originalsprache)
Data on percutaneous coronary intervention (PCI) for long chronic total occlusions (CTOs) are limited. We sought to identify temporal trends in PCI for long CTOs. We studied patients undergoing CTO-PCI between January 2015 and December 2022. Long CTO was defined as an occlusion length of ≥ 20 mm. The study population consisted of 10,302 patients, of whom 5,627 (54.6%) had a long CTO. Of these, 1,937 CTOs (34.4%) underwent primary retrograde approach and 1,486 CTOs (26.4%) underwent reverse controlled antegrade and retrograde tracking (CART). Reverse CART had a higher technical success rate than retrograde wiring and intravascular ultrasound (IVUS)-guided wiring after antegrade wiring (94.7%, 91.0%, and 81.6%, respectively), a longer guidewire crossing time (124, 92, and 85 min, respectively), and a higher incidence of coronary perforation (8.5%, 4.9%, and 6.3%, respectively) (P < 0.01 for all). For long CTOs with good distal landing without side branches, the use of primary retrograde approach and reverse CART decreased over time from 39.9% to 27.3% and from 36.3% to 20.1%, respectively, whereas the use of antegrade wiring and IVUS-guided wiring after antegrade wiring increased from 46.6% to 58.7% and from 1.0% to 8.7%, respectively (P for trend < 0.01 for all). In PCI for long CTOs, reverse CART was the most commonly used re-entry technique. For long CTOs with good distal landing without side branches, the use of primary retrograde approach and reverse CART decreased, whereas the use of antegrade wiring and IVUS-guided wiring after antegrade wiring increased.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Okayama, Japan. ht7307@kchnet.or.jp.
- Toyohashi Heart Center, Aichi, Japan.
- Saiseikai Yokohama-city Eastern Hospital, Kanagawa, Japan.
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
- Tokushima Red Cross Hospital, Tokushima, Japan.
- Seirei Hamamatsu General Hospital, Shizuoka, Japan.
ORCID-Profile: Hiroyuki Tanaka
Förderung
- Asahi Intecc
- Abbott Japan
- Biosensors Japan
- Boston Scientific Japan
- Daiichi-Sankyo
- Kaneka Medix
- Medtronic Japan
- Nipro
Zitieren
APA
Tanaka, H., Tsuchikane, E., Ito, Y., Sumitsuji, S., Kishi, K., Okada, H., Oikawa, Y., Yoshikawa, R., Kawasaki, T., & Katoh, O. (2026). Temporal trends and outcomes of long coronary chronic total occlusion interventions: the Japanese CTO-PCI expert registry. Cardiovascular Intervention and Therapeutics. https://doi.org/10.1007/s12928-025-01226-2
Vancouver
Tanaka H, Tsuchikane E, Ito Y, Sumitsuji S, Kishi K, Okada H, et al. Temporal trends and outcomes of long coronary chronic total occlusion interventions: the Japanese CTO-PCI expert registry. Cardiovascular Intervention and Therapeutics. 2026. doi:10.1007/s12928-025-01226-2
BibTeX
@article{Tanaka2026,
author = {Tanaka, Hiroyuki and Tsuchikane, Etsuo and Ito, Yoshiaki and Sumitsuji, Satoru and Kishi, Koichi and Okada, Hisayuki and Oikawa, Yuji and Yoshikawa, Ryohei and Kawasaki, Tomohiro and Katoh, Osamu},
title = {Temporal trends and outcomes of long coronary chronic total occlusion interventions: the Japanese CTO-PCI expert registry},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2026},
doi = {10.1007/s12928-025-01226-2}
}
EUVIMED